This article was originally posted on Sept. 1.
Roche last week said that the European Commission has approved the use of Tarceva as a first-line monotherapy for non-small cell lung cancer in patients with EGFR activating mutations.
Roche's diagnostic arm is developing a companion test to identify EGFR-mutation-positive patients for the drug. The company said it expects the CE Mark for the Cobas EGFR Mutation Test before the end of the year.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
